Maternal erythrocyte @entity1234 level in XXXX prediction: a longitudinal study.

@entity1 @entity1234 @entity1468
We aimed to determine the value of maternal erythrocyte @entity1234 levels in the prediction of @entity1468 . 110 healthy @entity1 were included in this prospective study. Maternal erythrocyte @entity1234 levels were measured at each trimester of pregnancy (10-14, 20-25 and 30-35 gestational weeks). On follow-up, @entity1 were assigned to two groups as normotensive @entity1 and preeclamptic @entity1 . @entity1468 had developed in eight (8.9%) of the 90 pregnant @entity1 who completed the study. Preeclamptic @entity1 were diagnosed between 36 and 39 gestational weeks (36.8 +/- 1.0 weeks). @entity1234 levels of preeclamptic @entity1 increased significantly in the third trimester (p < 0.05), while there was no difference between values of @entity1234 in the first and second trimester. @entity1234 levels were significantly higher in the @entity1 who developed @entity1468 than in those who did not in the third trimester (p < 0.05). With the use of the receiver operating characteristics (ROC) 35.98 nmol @entity1234 /gm hemoglobin was found to be a cut-off value predictive for the development of @entity1468 in the third trimester. However, cut-off values in the first and second trimesters could not be found. The sensitivity, specificity, positive and negative predictive values were 89, 75, 29 and 98%, respectively. @entity1468 risk was found to increase nearly 24 times in values above 35.98 nmol @entity1234 / gm hemoglobin. Our results showed that maternal erythrocyte @entity1234 could predict @entity1 within a few weeks prior to onset of clinical symptoms of @entity1468 in the third trimester. There is no evidence of enhanced early lipid peroxidation in pregnancies with late onset @entity1468 .
